GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ZyVersa Therapeutics Inc (NAS:ZVSA) » Definitions » Piotroski F-Score

ZVSA (ZyVersa Therapeutics) Piotroski F-Score : 3 (As of Dec. 12, 2024)


View and export this data going back to 2022. Start your Free Trial

What is ZyVersa Therapeutics Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ZyVersa Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for ZyVersa Therapeutics's Piotroski F-Score or its related term are showing as below:

ZVSA' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 3   Max: 3
Current: 3

During the past 4 years, the highest Piotroski F-Score of ZyVersa Therapeutics was 3. The lowest was 3. And the median was 3.


ZyVersa Therapeutics Piotroski F-Score Historical Data

The historical data trend for ZyVersa Therapeutics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZyVersa Therapeutics Piotroski F-Score Chart

ZyVersa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A N/A 3.00

ZyVersa Therapeutics Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 3.00 N/A 3.00 3.00

Competitive Comparison of ZyVersa Therapeutics's Piotroski F-Score

For the Biotechnology subindustry, ZyVersa Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZyVersa Therapeutics's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where ZyVersa Therapeutics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was -13.339 + -2.827 + -2.764 + -2.401 = $-21.33 Mil.
Cash Flow from Operations was -2.787 + -3.777 + -1.914 + -0.644 = $-9.12 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(32.852 + 22.114 + 21.651 + 19.47 + 19.424) / 5 = $23.1022 Mil.
Total Assets at the begining of this year (Sep23) was $32.85 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.39 Mil.
Total Current Liabilities was $11.54 Mil.
Net Income was -4.602 + -3.544 + -78.513 + -2.902 = $-89.56 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(2.346 + 118.506 + 114.954 + 31.988 + 32.852) / 5 = $60.1292 Mil.
Total Assets at the begining of last year (Sep22) was $2.35 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $2.01 Mil.
Total Current Liabilities was $11.71 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ZyVersa Therapeutics's current Net Income (TTM) was -21.33. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ZyVersa Therapeutics's current Cash Flow from Operations (TTM) was -9.12. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=-21.331/32.852
=-0.64930598

ROA (Last Year)=Net Income/Total Assets (Sep22)
=-89.561/2.346
=-38.17604433

ZyVersa Therapeutics's return on assets of this year was -0.64930598. ZyVersa Therapeutics's return on assets of last year was -38.17604433. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

ZyVersa Therapeutics's current Net Income (TTM) was -21.33. ZyVersa Therapeutics's current Cash Flow from Operations (TTM) was -9.12. ==> -9.12 > -21.33 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=0/23.1022
=0

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=0/60.1292
=0

ZyVersa Therapeutics's gearing of this year was 0. ZyVersa Therapeutics's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=0.39/11.542
=0.03378964

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=2.005/11.707
=0.17126506

ZyVersa Therapeutics's current ratio of this year was 0.03378964. ZyVersa Therapeutics's current ratio of last year was 0.17126506. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

ZyVersa Therapeutics's number of shares in issue this year was 0.988. ZyVersa Therapeutics's number of shares in issue last year was 0.097. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

ZyVersa Therapeutics's gross margin of this year was . ZyVersa Therapeutics's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=0/32.852
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=0/2.346
=0

ZyVersa Therapeutics's asset turnover of this year was 0. ZyVersa Therapeutics's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ZyVersa Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

ZyVersa Therapeutics  (NAS:ZVSA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


ZyVersa Therapeutics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of ZyVersa Therapeutics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ZyVersa Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Executives
Pablo A. Guzman officer: Chief Medical Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Katrin Rupalla director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Stephen C. Glover director, officer: Chief Executive Officer 108 DOCKSIDE CIRCLE, WESTON FL 33327
Labella Nicholas A. Jr. officer: Chief Scientific Officer C/O INSMED INCORPORATED, 8720 STONY POINT PKWY, SUITE 200, RICHMOND VA 23235
Peter Wolfe officer: Chief Financial Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Karen A. Cashmere officer: Chief Commercial Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Min-chul Park director C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Incon Co., Ltd. 10 percent owner 4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI M5 14042
Robert G Finizio director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Raj Mehra director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
David S. Briones director, officer: Chief Financial Officer C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Daniel J. O'connor director, officer: Chief Executive Officer C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
A.g.p. / Alliance Global Partners Corp. 10 percent owner 88 POST ROAD WEST, 2ND FLOOR, WESTPORT CT 06880

ZyVersa Therapeutics Headlines

From GuruFocus